A Semisynthetic Kanglemycin Shows In Vivo Efficacy against High-Burden Rifampicin Resistant Pathogens

[Image: see text] Semisynthetic rifamycin derivatives such as rifampicin (Rif) are first line treatments for tuberculosis and other bacterial infections. Historically, synthetic modifications made to the C-3/C-4 region of the rifamycin naphthalene core, like those seen in Rif, have yielded the bigge...

Descripción completa

Detalles Bibliográficos
Autores principales: Peek, James, Xu, Jiayi, Wang, Han, Suryavanshi, Shraddha, Zimmerman, Matthew, Russo, Riccardo, Park, Steven, Perlin, David S., Brady, Sean F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497472/
https://www.ncbi.nlm.nih.gov/pubmed/32786275
http://dx.doi.org/10.1021/acsinfecdis.0c00223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497472/
https://www.ncbi.nlm.nih.gov/pubmed/32786275
http://dx.doi.org/10.1021/acsinfecdis.0c00223

Ejemplares similares